St.-Gallen-Konferenz 2011 zum primären Mammakarzinom

Zusammenfassung

Alle 2 Jahre findet in St. Gallen die internationale Konsensuskonferenz zur Behandlung des primären Mammakarzinoms statt. Vor dem Hintergrund, dass das Konzept der St.-Gallen-Konsensuskonferenz v. a. ein internationales Meinungsbild widerspiegelt, erscheint es sinnvoll, die Abstimmungsergebnisse für den Therapiealltag in Deutschland zu konkretisieren. Eine Arbeitsgruppe von 28 Brustkrebsexperten, darunter 3 Mitglieder des internationalen St.-Gallen-Panels, hat daher die Abstimmungsergebnisse der diesjährigen St.-Gallen-Konsensuskonferenz (2011) aus deutscher Sicht kommentiert. Inhaltlicher Schwerpunkt der diesjährigen St.-Gallen-Konferenz war die Tumorbiologie als Ausgangspunkt für die individuelle Therapieentscheidung. Intensiver Diskussionsbedarf bestand bei der klinischen Relevanz prädiktiver und prognostischer Faktoren und den möglichen Konsequenzen für die Therapieentscheidung. So fokussierten insbesondere die Fragen zur Indikation einer adjuvanten Chemotherapie auf die Bedeutung des molekularen Phänotyps des Tumors. Wichtige Diskussionspunkte waren darüber hinaus der Stellenwert der kompletten Axilladissektion und der Einsatz der beschleunigten Gesamtbrustbestrahlung.

Abstract

Every 2 years, the International Consensus Conference on the Treatment of Primary Breast Cancer takes place in St. Gallen. Given that the concept of the St. Gallen Consensus Conference mainly reflects an international opinion, it appears useful to adapt the results of the vote for everyday therapy in Germany. A working group comprising 28 breast cancer experts, amongst whom there are 3 members of the international St. Gallen panel, has therefore commented on this year's St. Gallen Consensus Conference (2011) from the German viewpoint. The focus of interest of this year's St. Gallen Conference was tumour biology as the starting point for decisions regarding individual therapy. There was an intensive discussion in relation to the clinical relevance of predictive and prognostic factors and possible consequences for decisions regarding therapy. Therefore, questions concerning the indication for adjuvant chemotherapy focused especially on the significance of the molecular phenotype of the tumour. In addition, important points for discussion were also the value of complete axillary dissection and the use of accelerated complete breast irradiation.

frühes Mammakarzinom - endokrine Therapie - neoadjuvante Chemotherapie - zielgerichtete Therapie - prädiktive prognostische Marker

early breast cancer - endocrine therapy - neoadjuvant chemotherapy - targeted therapy - predictive prognostic marker

Literatur

• 1 Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.  JCO. 2006;  24 3726-3734
• 2 Albain K, Barlow W E, Ravdin P M et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial.  Lancet Oncol. 2010;  11 55-65
• 3 Lyman G L, Giuliano A E, Somerfield M R et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.  J Clin Oncol. 2005;  23 7703-7720
• 4 Whelan T, Pignol J P, Levine M N et al. Long-term results of hypofractionated radiation therapy for breast cancer.  N Engl J Med. 2010;  362 513-520
• 5 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.  Lancet. 2005;  365 1687-1717
• 6 Nitz U et al. Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase lll trial EC-Doc. SABCS2008; Abstract No. 551601
• 7 Moebus V, Jackisch C, Lueck H J et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.  J Clin Oncol. 2010;  28 2874-2880
• 8 Slamon D et al. Use of trastuzumab in the adjuvant treatment of HER2-positive breast cancer: efficacy and safety results from the BCIRG-006 study.  NEJM. 2011;  in press
• 9 Naume B, Sorlie T. Molecular profiling of early breast cancer in relation to detection of micrometastases and outcome.  Breast Cancer Research. 2005;  7 (Suppl. 2) 35